新型超声探头机器人辅助前列腺活检
机器人辅助前列腺活检与新型超声探头
Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in PCa diagnosis without overdetection and overtreatment include targeted biopsy techniques for clinically significant PCa using magnetic resonance imaging (MRI), and precision targeted biopsy guided by ultrasound and fused to the MRI.
The study aims to improve prostate biopsy with a novel ultrasound probe and robot developed at Johns Hopkins, the ProBot device. The trial is a Phase 1 clinical trial to evaluate the safety and feasibility of the new device.
ProBot is an entirely new concept including a novel ultrasound probe and robot kinematics specifically designed for the prostate. It operates with only two degrees of freedom configured such that the motions for 3D image scanning and biopsy may not deform the prostate gland, thus improving the accuracy of MRI-ultrasound fusion and needle targeting at biopsy.
ProBot is a small and lightweight robot (1.3Kg including the ultrasound probe). It allows hands-free operation of its ultrasound probe at 3D image scanning and needle targeting supervised by the urologist.
In addition to MRI-targeted biopsy (TB), at systematic biopsy (SB), instead of using the common template plan that is the same for all patients, the innovative software optimizes the plan for each patient to obtain a diagnosis that is representative of the whole gland histology. The ProBot robot is also uniquely capable of transrectal (TR) and transperineal (TP) biopsy.
The aims of the study are to determine the safety and feasibility of the new device at TR and TP biopsies.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Rana Harb
- 电话号码:410-502-5500
- 邮箱:rharb1@jhmi.edu
研究联系人备份
- 姓名:Sara A Naizghi
- 电话号码:720-965-9494 4105501980
- 邮箱:snaizgh1@jh.edu
学习地点
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins Hospital
-
接触:
- Rana Harb
- 电话号码:410-502-5500
- 邮箱:rharb1@jhmi.edu
-
接触:
- Sara A Naizghi
- 电话号码:720-965-9494
- 邮箱:snaizgh1@jh.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Included in the study will be:
-
Men between the ages of 40 and 75
-
Men must have one of the following "high risk" features:
- PSA > 4.0 ng/ml and/or abnormal digital rectal examination (DRE)
- ASAP (atypical small acinar proliferation) on previous biopsy
-
Men with mpMRI or bpMRI exams, including both PI-RADS ≤2 and PI-RADS ≥3.
Excluded from the study will be patients without available mpMRI exams and patients:
-
Females and children because of the prostate cancer targeted disease.
-
Patients who are not recommended or in whom TR or TP prostate biopsy is considered high-risk:
- Patients with previous rectal surgery.
- Patients with anal stenosis or coagulopathy.
- Patients on active anticoagulation medication (eg. Coumadin, Lovenox, or Heparin).
- Patients who cannot tolerate periprostatic Lidocaine block anesthesia or in whom anesthesia is considered high-risk.
-
Patients who already had a prostate biopsy taken with the ProBot investigational device.
-
Vulnerable populations, such as prisoners, institutionalized individuals.
-
Patients who are unwilling or unable to sign informed consent (no assent required).
学习计划
研究是如何设计的?
设计细节
- 主要用途:设备可行性
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Transrectal biopsy (TR)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transrectal path |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
|
实验性的:Transperineal biopsy (TP)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transperineal path. |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Device feasibility as assessed by patient discomfort score
大体时间:Immediately after the procedure
|
Scale 1-10, 10 highest discomfort |
Immediately after the procedure
|
|
Device feasibility as assessed by maximal procedural pain
大体时间:Immediately after the procedure
|
Scale 1-10, 10 highest pain |
Immediately after the procedure
|
|
Device feasibility as assessed by the rate of complications
大体时间:Throughout the study, each case recorded within 1 month of the procedure
|
Rate of complications |
Throughout the study, each case recorded within 1 month of the procedure
|
|
Device feasibility as assessed by serious adverse events
大体时间:Up to 1 month post procedure
|
Serious Adverse events throughout the study |
Up to 1 month post procedure
|
|
Device feasibility as assessed by the rate of successful completion of cases
大体时间:Immediately post procedure
|
Rate of cases completed successfully throughout the study |
Immediately post procedure
|
|
Device feasibility as assessed by the procedure time
大体时间:Immediately post procedure
|
Times of the procedures measured in minutes throughout the study |
Immediately post procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prostate cancer detection rates at targeted biopsy (TB)
大体时间:Up to 1 month post procedure
|
Clinically significant PCa detection rates at TB throughout the study |
Up to 1 month post procedure
|
|
Prostate cancer detection rates at systematic biopsy (SB)
大体时间:Up to one month post procedure
|
Clinically significant PCa detection rates at SB throughout the study |
Up to one month post procedure
|
|
Needle targeting errors
大体时间:Immediately post procedure
|
Measured in ultrasound throughout the study |
Immediately post procedure
|
|
Prostate deformations (mm)
大体时间:Immediately post procedure
|
Maximum deformation of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
|
Prostate displacement (mm)
大体时间:Immediately post procedure
|
Displacement of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
合作者和调查者
调查人员
- 首席研究员:Misop Han, MD、Johns Hopkins University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.